The University of Texas Health Science Center, Houston
The purpose of this study is to determine the effects of suvorexant (SUVO), on sleep, stress, and drug craving during early abstinence from stimulants and to determine the effects of treatment (SUVO vs. treatment as usual (TAU)) on post-treatment (Days 13-30) residential program length of stay (LOS) and completion rate.
Inclusion Criteria: * Meet Diagnostic and Statistical Manual of Mental Disorders(DSM-5)criteria for primary stimulant use disorder (either cocaine or methamphetamine) * Be fluent in English and able to understand the consent form Exclusion Criteria: * Have an opioid use disorder of any severity * Have a greater than moderate substance use disorder on any other substance * Undergoing medication-assisted treatment for withdrawal of any substance * Have any medical conditions contraindicating SUVO (e.g., severe pulmonary disease, severe cardiovascular disease or clinically abnormal ECG, severe…
Participants will receive 20mg of SUVO for 7 days in the evening before bed on Day 5 through Day 11
Participants will receive supportive care and symptomatic medication per protocol at the inpatient facility.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.